HeartSciences Faces Nasdaq Delisting After Equity Shortfall

summarizeSummary

HeartSciences received a Nasdaq delisting notice for falling short of the $2.5M stockholders' equity requirement. Its sole plan to regain compliance hinges on the pending merger with Fortitude Mining, turning the merger vote into an existential event.

check_boxKey Events · Legal and Risk Events · HSCS

• Nasdaq Delisting Notice Received

  On August 4, 2026, Nasdaq notified HeartSciences that it fails the $2.5M stockholders' equity requirement, with equity standing at just $226,060 as of April 30, 2026.

• Compliance Plan Deadline

  HeartSciences has until September 18, 2026 to submit a plan to regain compliance; if the plan is accepted, the company may receive an extension until January 31, 2027 to execute it.

• Merger Is Only Path to Compliance

  The company states its plan relies on consummating the all-stock merger with Fortitude Mining Holdings; failure to close the deal would likely result in delisting.

• Delisting Would Threaten Merger

  Nasdaq suspension or delisting would reduce liquidity, impair financing access, and negatively impact the ability to complete the Proposed Transaction.

auto_awesomeAnalysis · HSCS · Crypto Assets

A Nasdaq delisting notice landed after HeartSciences disclosed stockholders' equity of just $226,060 — a fraction of the $2.5 million minimum. The company now has 45 days to submit a compliance plan, and its entire strategy rests on the pending merger with Fortitude Mining. Should that deal collapse, delisting becomes nearly inevitable, which would crush liquidity and likely scuttle the transaction. This is a binary outcome: the merger is the only realistic path to survival, and time is running out.